These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 11075394)

  • 21. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody.
    Nishida K; Okada Y; Nawata M; Saito K; Tanaka Y
    Endocr J; 2008 Mar; 55(1):213-6. PubMed ID: 18270431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating rheumatoid arthritis with tumour necrosis factor alpha blockade.
    Emery P; Buch M
    BMJ; 2002 Feb; 324(7333):312-3. PubMed ID: 11834544
    [No Abstract]   [Full Text] [Related]  

  • 23. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TNF-alpha inhibition: the need for a tumor necrosis factor thermostat.
    O'Dell JR
    Mayo Clin Proc; 2001 Jun; 76(6):573-5. PubMed ID: 11393494
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of rheumatoid arthritis by TNF-blocking agents.
    Graninger W; Smolen J
    Int Arch Allergy Immunol; 2002 Jan; 127(1):10-4. PubMed ID: 11893849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ten years of infliximab (remicade) in clinical practice: the story from bench to bedside.
    Cornillie F
    Eur J Pharmacol; 2009 Nov; 623 Suppl 1():S1-4. PubMed ID: 19837054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
    Maini RN; Taylor PC; Paleolog E; Charles P; Ballara S; Brennan FM; Feldmann M
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I56-60. PubMed ID: 10577974
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunological therapies for rheumatoid arthritis.
    Edwards CJ
    Br Med Bull; 2005; 73-74():71-82. PubMed ID: 16174791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.
    Jit M; Henderson B; Stevens M; Seymour RM
    Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ten years of infliximab: insights from clinical trials in rheumatoid arthritis.
    Smolen JS
    Eur J Pharmacol; 2009 Nov; 623 Suppl 1():S5-9. PubMed ID: 19843471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Innovative approaches in therapy of chronic polyarthritis].
    Keysser G; Burmester GR
    Fortschr Med; 1995 Mar; 113(7):77-80. PubMed ID: 7750887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B
    J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intestinal necrosis in a patient with rheumatoid arthritis receiving anti-TNF treatment.
    Ruppert M; De Clerck L; van Offel J; Hubens G; Balliu L; Vaneerdeweg W
    Acta Chir Belg; 2006; 106(2):225-7. PubMed ID: 16761484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy.
    Boers M;
    Arthritis Rheum; 2001 Nov; 44(11):2703-4. PubMed ID: 11710727
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
    Cairns AP; Taggart AJ
    Ulster Med J; 2002 Nov; 71(2):101-5. PubMed ID: 12513005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis.
    Leandro MJ
    Arthritis Res Ther; 2009; 11(5):128. PubMed ID: 19818166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
    Baumgartner SW
    South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.